Topic

) and and Lavan Thasarathakumar, Thasa Consulting.

Articles

Hannah Schofield and Lavan Thasarathakumar discuss what blockchain is, how it could help improve pharmaceutical supply chains, and the COVID-19 vaccine supply chain in particular, and touches on where we are already seeing blockchain technology being used in this area.

Blockchain, COVID-19 and the Pharmaceutical Supply Chain

To effectively combat the looming threat of antimicrobial resistance, we must prioritize working together to strengthen and more responsibly manage global supply chains.


Better Supply Chains Can Better Tackle Threats to Public Health

Jill Wechsler is Pharm Exec's Washington Corespondent

The drive for “vaccine equity” around the world is bolstering efforts to limit patent protections on innovative medicines and vaccines to combat the global pandemic.

Pharma Prices & Patents Under Attack

A NASEM report for CDER outlines strategies to modernize pharmaceutical manufacturing to ensure reliable access to high-quality drugs, particularly in response to disruptions caused by the pandemic.

Pandemic Highlights Need for Advanced Pharma Manufacturing

, a Swiss-based global biopharmaceutical company.

Insights and examples of how collaborative efforts can lead to the development of innovative therapies that target unmet patient needs.

The Importance of Collaborative Business Models for Drug Development

New data comparing past vs. present experience with telemedicine during the pandemic uncovers insight on how patients, doctors, and payers view the market post-COVID.

The Future of Telehealth: Evolving COVID Perspectives Offer Clues

Jenifer Slaw is SVP of Media Relations at Goodfuse.

Dean Mastrojohn is SVP of Media Relations at Goodfuse.

at some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?

Silver Linings of a Global Health Crisis: A New Path Forward for Pharma Media Professionals

Ahmed Bouzidi is VP of Biotech Strategic Development at ProductLife Group (PLG). He has been at the forefront of the biopharma industry for more than 30 years, in three continents. He is a Senior Associate of the Royal Society of Medicines, and previously has been President of the European Biopharmaceutical Enterprises (EBE), and a board member of Vaccines Europe (VE).

Ahmed Bouzidi explores the opportunities and challenges facing small and mid-size biopharma companies as they strive to bring their latest innovations to market.

The Biopharma SME Revolution: Opportunities & Challenges Post-COVID

It’s important that care for people with pre-existing conditions or at risk from serious diseases does not fall by the wayside.

Action Through Engagement: Alleviating COVID Concerns in Patients with Underlying Conditions

Paul Rubin is partner at Debevoise & Plimpton and co-chair of the firm’s Healthcare & Life Sciences Group. Jacob W. Stahl is counsel in Debevoise & Plimpton’s New York office and a member of the firm’s Litigation Department. Melissa Runsten is a corporate associate at the firm and a member of the Healthcare & Life Sciences Group.

Assessing the implications for the pharma industry of the America Rescue Plan Act of 2021, which provides nearly two trillion dollars in funding for various government programs, including many related to public health.